We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+10.9%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.81B
AUM Growth
+$244M
Cap. Flow
-$21.2M
Cap. Flow %
-0.56%
Top 10 Hldgs %
49.66%
Holding
160
New
23
Increased
21
Reduced
32
Closed
35

Top Buys

Rank Stock Value
1
VRCA icon
Verrica Pharmaceuticals
VRCA
+$66.8M
2
MGTX icon
MeiraGTx Holdings
MGTX
+$63.1M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$56.2M
4
ISRG icon
Intuitive Surgical
ISRG
+$41.2M
5
KDMN
Kadmon Holdings, Inc.
KDMN
+$31.2M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$107M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$47.9M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$34.2M
4
ANAB icon
AnaptysBio
ANAB
+$24.7M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.91%
2 Industrials 0.65%
3 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
101
DELISTED
Loxo Oncology, Inc
LOXO
$653K 0.02%
+3,765
New +$566K
GTHX
102
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$611K 0.02%
+14,055
New +$602K
ADAP
103
DELISTED
Adaptimmune Therapeutics
ADAP
$585K 0.02%
+49,302
New +$615K
COLL icon
104
Collegium Pharmaceutical
COLL
$1.18B
$577K 0.02%
+24,213
New +$595K
VRAY
105
DELISTED
ViewRay, Inc.
VRAY
$519K 0.01%
75,000
-25,000
-25% -$182K
MNTA
106
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$501K 0.01%
+24,489
New +$526K
SENS icon
107
Senseonics Holdings Inc
SENS
$254M
$473K 0.01%
5,750
– –
ADVM
108
DELISTED
Adverum Biotechnologies
ADVM
$428K 0.01%
8,085
– –
IMUX icon
109
Immunic
IMUX
$178M
$405K 0.01%
+375
New +$867K
CASI
110
DELISTED
CASI Pharmaceuticals
CASI
$360K 0.01%
4,368
– –
SGMO
111
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$355K 0.01%
25,000
– –
VRNA
112
DELISTED
Verona Pharma
VRNA
$307K 0.01%
22,327
-33,841
-60% -$569K
HCM icon
113
HUTCHMED
HCM
$1.96B
$301K 0.01%
10,000
– –
NKTR icon
114
Nektar Therapeutics
NKTR
$2.39B
$296K 0.01%
404
– –
SYRE icon
115
Spyre Therapeutics
SYRE
$8.5B
$272K 0.01%
+1,028
New +$253K
VCEL icon
116
Vericel Corp
VCEL
$2.38B
$264K 0.01%
27,211
– –
TGTX icon
117
TG Therapeutics
TGTX
$8.19B
$258K 0.01%
+100,000
New +$1.38M
GRCE
118
Grace Therapeutics
GRCE
$33.8M
$117K ﹤0.01%
4,306
+419
+11% +$16.1K
ONCS
119
DELISTED
OncoSec Medical Incorporated
ONCS
$69K ﹤0.01%
227
– –
ELOX
120
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$50K ﹤0.01%
+74
New +$48K
CAPR icon
121
Capricor Therapeutics
CAPR
$380M
$5K ﹤0.01%
400
– –
ACAD icon
122
Acadia Pharmaceuticals
ACAD
$4.51B
– –
-275,000
Closed -$6.18M
AGIO icon
123
Agios Pharmaceuticals
AGIO
$2.08B
– –
-250,000
Closed -$20.4M
ANAB icon
124
AnaptysBio
ANAB
$1.54B
– –
-237,281
Closed -$24.7M
AVDL
125
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-1,295,841
Closed -$9.45M
3 4
5
6 7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Perceptive Advisors held 160 positions worth $3.81B, up 6.8% from $3.57B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q2 2018 filing shows 23 new, 21 increased, 32 reduced and 35 closed positions. Its largest new stake was Verrica Pharmaceuticals: 341,041 shares worth $67.3M. The largest sale was Abiomed Inc, an estimated $107M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier, followed by Industrials and Consumer Discretionary.

  • Perceptive Advisors's largest Q2 2018 buy was Verrica Pharmaceuticals: 341,041 shares worth $67.3M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2018, an estimated $56.2M increase.
  • Perceptive Advisors's biggest Q2 2018 reduction was Abiomed Inc, cutting an estimated $107M.
  • Perceptive Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $34.2M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.81B portfolio in Q2 2018.
  • Perceptive Advisors opened 23 new positions and closed 35 in Q2 2018.
  • Perceptive Advisors's portfolio value rose 6.8% quarter-over-quarter to $3.81B.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.